|
Feature
|
Total (N)
|
VISTA
|
P
|
VISTA (tumor cell)
|
P
|
VISTA (immune cell)
|
P
|
|---|
|
Pos (n, %)
|
Neg (n, %)
|
Pos (n, %)
|
Neg (n, %)
|
Pos (n, %)
|
Neg (n, %)
|
|---|
|
Age(years)
|
|
> 50
|
108
|
36(33.3%)
|
72(66.7%)
|
0.173
|
20(18.5%)
|
68(81.5%)
|
0.351
|
22(20.4%)
|
86(79.6%)
|
0.138
|
|
≤ 50
|
75
|
18(24.0%)
|
57(76.0%)
| |
10(13.3%)
|
65(86.7%)
| |
9(12.0%)
|
66(88.0%)
| |
|
Gender
|
|
Male
|
157
|
48(30.6%)
|
109(69.4%)
|
0.438
|
27(17.2%)
|
130(82.8%)
|
0.470
|
28(17.8%)
|
129(82.2%)
|
0.428
|
|
Female
|
26
|
6(23.1%)
|
20(76.9%)
| |
3(11.5%)
|
23(88.5%)
| |
3(11.5%)
|
23(88.5%)
| |
|
Tumor size
|
|
≤ 5 cm
|
91
|
31(34.1%)
|
60(65.9%)
|
0.804
|
20(22.0%)
|
71(78.0%)
|
0.042*
|
19(20.9%)
|
72(79.1%)
|
0.158
|
|
> 5 cm
|
92
|
23(25.0%)
|
69(75.0%)
| |
10(10.9%)
|
82(89.1%)
| |
12(13.0%)
|
80(87.0%)
| |
|
TNM stage
|
|
I
|
73
|
25(34.2%)
|
48(65.8%)
|
0.294
|
13(17.8%)
|
60(82.8%)
|
0.272
|
17(23.3%)
|
56(76.7%)
|
0.261
|
|
II
|
60
|
14(23.3%)
|
46(76.7%)
| |
7(11.7%)
|
53(88.3%)
| |
8(13.3%)
|
52(86.7%)
| |
|
III-IV
|
42
|
15(35.7%)
|
27(64.3%)
| |
10(23.8%)
|
32(76.2%)
| |
6(14.3%)
|
36(85.7%)
| |
|
Pathological grade
|
|
I-II
|
119
|
29(24.4%)
|
90(75.6%)
|
0.038*
|
16(13.4%)
|
103(86.6%)
|
0.142
|
18(15.1%)
|
101(84.9%)
|
0.372
|
|
III-IV
|
64
|
25(39.1%)
|
39(60.9%)
| |
14(21.9%)
|
50(78.1%)
| |
13(20.3%)
|
51(79.7%)
| |
|
Liver cirrhosis
|
|
Yes
|
69
|
26(22.8%)
|
88(77.2%)
|
0.011*
|
13(11.4%)
|
101(88.6%)
|
0.019*
|
17(14.9%)
|
97(85.1%)
|
0.347
|
|
No
|
114
|
28(40.6%)
|
41(59.4%)
| |
17(24.6%)
|
52(75.4%)
| |
14(20.3%)
|
55(79.7%)
| |
|
CD8+TILs
|
|
Yes
|
61
|
31(50.8%)
|
30(49.2%)
|
0.000*
|
19(31.1%)
|
42(68.9%)
|
0.000*
|
18(29.5%)
|
43(70.5%)
|
0.001*
|
|
No
|
122
|
23(18.9%)
|
99(81.1%)
| |
11(9.0%)
|
111(91.0%)
| |
13(10.7%)
|
109(89.3%)
| |
- VISTA V-domain Ig suppressor of T cell activation, Pos positive, Neg negative, HCC hepatocellular carcinoma, TILs tumor-infiltrating lymphocytes
- *The values had statistically significant differences
